This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
16 Feb 2015

Actavis Launches Generic Pulmicort Respules

Actavis has launched its generic version of AstraZeneca's Pulmicort Respules (budesonide inhalation suspension) 0.25 and 0.5 mg vials following a ruling from the US District Court for the District of New Jersey that (i) US Patent No. 7,524,834 is invalid, and (ii) AstraZeneca's request for a permanent injunction is denied.

 

Actavis' Abbreviated New Drug Application (ANDA) for its generic version of Pulmicort Respules received final approval from the FDA in August 2012.

 

Pulmicort Respules is a maintenance medicine used to control and prevent asthma symptoms in children ages 12 months to 8 years. For the 12 months ended June 30, 2014 total US brand and generic sales of Pulmicort Respules were approximately $1.1 billion. 

Related News